Suchergebnisse - "De Giorgi, Ugo"

PubPharm (83)

1

Impact of Metastatic Site in Favorable-Risk Renal Cell Carcinoma Receiving Sunitinib or Pazopanib

enthalten in: Clinical genitourinary cancer | 2024

von Catalano, M. | De Giorgi, U. | Bimbatti, D. | +9

2

Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype : A Randomized Phase III Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Lorusso, D. | Raspagliesi, F. | Ronzulli, D. | +20

3

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

enthalten in: The New England journal of medicine | 2024

von Powles, T. | Valderrama, B. | Gupta, S. | +122

4

Instrumental activities of daily living in older patients with metastatic prostate cancer : results from the meet-URO network ADHERE prospective study

enthalten in: Scientific reports | 2024

von Fratino, L. | Polesel, J. | Giunta, E. | +16

5

Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

enthalten in: Journal of hepatology | 2024

von Celsa, C. | Cabibbo, G. | Fulgenzi, C. | +69

6

Pregnancy After Breast Cancer in Young BRCA Carriers : An International Hospital-Based Cohort Study

enthalten in: JAMA | 2024

von Lambertini, M. | Blondeaux, E. | Agostinetto, E. | +152

CommentIn: JAMA. 2024 Apr 9;331(14):1233-1234. - PMID 38592393

7

Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab

enthalten in: JAMA network open | 2023

von Catalano, M. | Rebuzzi, S. | Maruzzo, M. | +31

8

Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations

enthalten in: Minerva urology and nephrology | 2023

von Porta, C. | Bamias, A. | Zakopoulou, R. | +63

9

Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma : does it affect outcome?

enthalten in: Expert review of anticancer therapy | 2023

von Corianò, M. | Giannarelli, D. | Scartabellati, G. | +21

10

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3) : a multicentre, open-label, randomised, controlled, phase 2 trial

enthalten in: The Lancet. Oncology | 2023

von Pignata, S. | Scambia, G. | Schettino, C. | +128

CommentIn: Lancet Oncol. 2023 Mar;24(3):201-203. - PMID 37052963

1
2
3
4
5
6
7
8
9
Nächster »
[9]